Keele, UK: Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that it has signed an agreement with ViroMed Co., Ltd. in Korea to produce VM206RY, a plasmid DNA treatment for tumours expressing Her2/neu (breast, ovarian, pancreatic, and stomach cancers). Under the agreement, Cobrabio will produce ViroMed’s Master Cell Bank and GMP-grade VM206RY for clinical trials which will be held in Korea and in the United States.
Simon Saxby, Chief Executive of Cobra Biomanufacturing said:
“We are delighted to continue our partnership with ViroMed. In a recent ViroMed project, Cobrabio demonstrated that our commitment to world class science, cGMP quality compliance and customer service provides the additional resources that leading biotech companies such as ViroMed require to drive their research and development programmes forward. ViroMed is Cobra’s first client in Asia and we are pleased to extend our services to this fast-growing life sciences market.”
Dr. Sunyoung Kim, CEO of ViroMed Co., Ltd. said:
“We are pleased to extend our relationship with Cobrabio to our VM206RY plasmid project. ViroMed is a rapidly expanding company with a growing pipeline of products in development and it is vital that we work with partners who can match our scientific expertise as well as our commitment to quality.”
For further information, please contact:
Cobra Biomanufacturing Plc Tel: +44 (0) 1782 714 181
Simon Saxby, Chief Executive Officer
Buchanan Communications Tel: +44 (0) 207 466 5000
Tim Anderson/Rebecca Skye Dietrich
College Hill Life Sciences Tel: +44 (0) 1260 296 506
Kathryn Robertson
Seymour Pierce (NOMAD & Broker) Tel: +44 (0) 207 107 8000
Stuart Lane
About Cobra Biomanufacturing Plc:
Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products.
Cobrabio has developed a range of unique, patented technologies, which underpin a successful revenue generating contract manufacturing business.
www.cobrabio.com
